menu search

CRVS / Corvus Pharmaceuticals, Inc. (CRVS) Q4 2022 Earnings Call Transcript

Corvus Pharmaceuticals, Inc. (CRVS) Q4 2022 Earnings Call Transcript
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q4 2022 Earnings Conference Call March 27, 2023 4:30 PM ET Company Participants Zack Kubow - Investor Relations-Real Chemistry Leiv Lea - Chief Financial Officer Richard Miller - Co-Founder, President & Chief Executive Officer James Rosenbaum - Senior Vice President-Research Conference Call Participants Mara Goldstein - Mizuho Roger Song - Jefferies Operator Good afternoon, ladies and gentlemen. Thank you for standing by, and welcome to the Corvus Pharmaceuticals Fourth Quarter and Full Year 2022 Business Update and Financial Results Conference Call. Read More
Posted: Mar 28 2023, 22:55
Author Name: Seeking Alpha
Views: 112537

CRVS News  

Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition

By GlobeNewsWire
November 2, 2023

Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition

BURLINGAME, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today more_horizontal

Corvus Pharmaceuticals, Inc. (CRVS) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 8, 2023

Corvus Pharmaceuticals, Inc. (CRVS) Q2 2023 Earnings Call Transcript

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q2 2023 Earnings Call Transcript August 8, 2023 4:30 PM ET Company Participants Zack Kubow - IR-Real Chemi more_horizontal

Corvus Pharmaceuticals: Targeting $1 Billion/Year U.S. T-Cell Lymphoma Market

By Seeking Alpha
May 12, 2023

Corvus Pharmaceuticals: Targeting $1 Billion/Year U.S. T-Cell Lymphoma Market

Additional Phase 1b data for CPI-818 in T cell lymphoma is expected in this quarter. Phase 2 data for Ciforadenant is expected this year. more_horizontal

Corvus Pharmaceuticals, Inc. (CRVS) Q4 2022 Earnings Call Transcript

By Seeking Alpha
March 28, 2023

Corvus Pharmaceuticals, Inc. (CRVS) Q4 2022 Earnings Call Transcript

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q4 2022 Earnings Conference Call March 27, 2023 4:30 PM ET Company Participants Zack Kubow - Investor Rela more_horizontal

Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 28, 2023

By GlobeNewsWire
March 21, 2023

Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 28, 2023

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT more_horizontal

Corvus Pharmaceuticals, Inc. (CRVS) Q3 2022 Earnings Call Transcript

By Seeking Alpha
November 6, 2022

Corvus Pharmaceuticals, Inc. (CRVS) Q3 2022 Earnings Call Transcript

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Zack Kubow - Investor Re more_horizontal

Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q4 2021 Results - Earnings Call Transcript

By Seeking Alpha
March 10, 2022

Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q4 2021 Results - Earnings Call Transcript

Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q4 2021 Results - Earnings Call Transcript more_horizontal


Search within

Pages Search Results: